Download PDF
Thromb Haemost 1995; 73(05): 798-804
DOI: 10.1055/s-0038-1653871
Original Articles
Coagulation
Schattauer GmbH Stuttgart

Synchronized Inhibition of the Phospholipid Mediated Autoactivation of Factor XII in Plasma by β2-glycoprotein I and Anti-β2-glycoprotein I

Inger Schousboe
The Department of Medical Biochemistry and Genetics, Laboratory C, The Panum Institute, University of Copenhagen, Copenhagen, Denmark
,
Margit Søe Rasmussen
The Department of Medical Biochemistry and Genetics, Laboratory C, The Panum Institute, University of Copenhagen, Copenhagen, Denmark
› Author Affiliations
Further Information

Publication History

Received 19 August 1994

Accepted after revision 17 January 1995

Publication Date:
09 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Lupus anticoagulants are a group of antibodies commonly found in patients with autoimmune diseases such as systemic lupus erythematosus. Lupus anticoagulants inhibit phospholipid dependent coagulation and may bind to negatively charged phospholipids. Recent studies have suggested an association between anti-β2-glycoprotein I and a lupus anticoagulant, whose activity is frequently dependent on the presence of β2-glycoprotein I. Based on these observations, the effect of anti-β2-glycoprotein I on the autoactivation of factor XII in plasma was investigated. Autoactivation initiated by the presence of negatively charged phospholipids, but not by sulfatide, was strongly inhibited by immunoaffinity purified anti-β2-glycoprotein I. The dose-response curve of anti-β2-gly coprotein I was identical with that of a precipitating antibody, showing no inhibition at low and high antibody dilutions and maximal inhibition at an intermediate dilution. At high antibody concentrations, an increased rate of factor Xlla activation was observed. This increase was of the same magnitude as the decreased rate observed in plasma supplemented with the same amount of β2-glycoprotein I as in the plasma itself. This confirms the inhibitory effect of β2-GP-I on the contact activation and shows that inhibition is effective on the autoactivation of factor XII in plasma. The inhibitory action of β2-glycoprotein I was independent of the inhibition caused by the anti- β2-glycoprotein I/β2-glycoprotein I complex suggesting a synchronized inhibition of factor XII autoactivation by β2-glycoprotein I and anti-β2-gly coprotein I. The inhibition caused by the antibody is suggested to be caused by a reduced availability of negatively charged phospholipids due to the binding of the anti-β2- GP-I/β2-GP-I complex. This complex may be a lupus anticoagulant.

 

  • References

  • 1 Reyes H, Dearing L, Shoenfeld Y, Peter JB. Antiphospholipid antibodies: A critique of their heterogeneity and hegonomy. Sent Thromb Haemost 1994; 20: 89-100
    PubMedGoogle Scholar
  • 2 Triplett DA, Brandt JT. Laboratory identification of The lupus anticoagulant. Br J Haematol 1989; 73: 139-142
    CrossrefPubMedGoogle Scholar
  • 3 Lupus Anticoagulant Working Party: Guidelines on testing for Lupus anticoagulant. J Clin Pathol 1991; 44: 885-889
    CrossrefPubMed
  • 4 Harris EN. Antiphospholipid antibodies. Br J Haematol 1990; 74: 1-9
    PubMedGoogle Scholar
  • 5 Harris EN, Gharavi AE M, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, Hughes GR. Anticardiolipin antibodies: Detection by radio-immunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 2: 1211-1214
    PubMedGoogle Scholar
  • 6 Triplett DA, Brandt JT, Musgrave KA, Orr CA. Relationship between Lupus anticoagulants and antibodies to phospholipids. JAMA 1988; 259: 550-554
    CrossrefPubMedGoogle Scholar
  • 7 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipidbinding inhibitor of coagulation: β2Glycoprotein-I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4124
    CrossrefPubMedGoogle Scholar
  • 8 Galli M, Comfurius P, Maassen C, Hemker HC, de BaetsM, van Breda-Vriesman PJ C, Barbui T, Zwaal RF, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-1547
    CrossrefPubMedGoogle Scholar
  • 9 Schousboe I. Purification, characterization and identification of an agglutinin in human serum. Biochim Biophys Acta 1979; 579: 396-408
    CrossrefPubMedGoogle Scholar
  • 10 Schousboe I. Characterization of the interaction between β2-Glycoprotein-I and mitochondrie, platelets, liposomes and bile acids. Int J Biochem 1983; 15: 1393-1401
    CrossrefPubMedGoogle Scholar
  • 11 Wurm H. ß2-Glycoprotein I (Apolipoprotein H): Interactions with phospholipid vesicles. Int J Biochem 1984; 16: 511-515
    CrossrefPubMedGoogle Scholar
  • 12 Rauch J, Janoff AS. Phospholipid in the hexagonal II phase is immunogenic: Evidence for immunorecognition of nonbilayer lipid phases in vivo. Proc Natl Acad Sci USA 1990; 87: 4112-4114
    CrossrefPubMedGoogle Scholar
  • 13 Rauch J, Tannenbaum M, Tannambaum H, Ramelson H, Cullis PR, Tilcock CP S, Hope MJ, Janoff AS. Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase lipid systems. J Biol Chem 1986; 261: 9672-9677
    PubMedGoogle Scholar
  • 14 Rauch J, Tannenbaum M, Janoff AS. Distinguishing plasma lupus anticoagulants from anti-factor antibodies using hexagonal (II) phase phospholipids. Thromb Haemost 1989; 62: 892-896
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Arvieux J, Pouzol P, Roussel B, Jacob MC, Colomb MG. Lupus-like anticoagulant properties of murine monoclonal antibodies to β2-glycoprotein I. Brit J Haemat 1992; 81: 568-573
    CrossrefPubMedGoogle Scholar
  • 16 Gharavi AE, Sammaritano LR, Wen J, Elkon KB. Induction of antiphospholipid autoantibodies by immunization with β2-glycoprotein I (Apolipoprotein H). J Clin Invest 1992; 90: 1105-1109
    CrossrefPubMedGoogle Scholar
  • 17 Pierangeli SS, Harris EN. Induction of phospholipid-binding antibodies in mice and rabbits by immunization with human β2-glycoprotein I or anticardiolipin antibodies alone. Clin Exp Immunol 1993; 93: 269-272
    CrossrefPubMedGoogle Scholar
  • 18 Viard J-P, Amoura Z, Bach J-F. Association of anti-β2-glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med 1992; 93: 181-186
    CrossrefPubMedGoogle Scholar
  • 19 Schousboe I. β2-Glycoprotein-I: A plasma inhibitor of contact activation of the intrinsic blood coagulation pathway. Blood 1985; 66: 1085-1091
    PubMedGoogle Scholar
  • 20 Henry ML, Everson B, Ratnoff OD. Inhibition of the activation of Hageman factor (factor XII) by β2-Glycoprotein I. J Lab Clin Med 1988; 111: 519-523
    PubMedGoogle Scholar
  • 21 Schousboe I. Inositolphospholipid-accelerated activation of prekallikrein by activated factor XII and its inhibition by β2-glycoprotein I. Eur J Biochem 1988; 176: 629-636
    CrossrefPubMedGoogle Scholar
  • 22 Nimpf J, Bevers EM, Bomans PH H, Till U, Wurm H, Kostner GM, Zwaal RF A. Prothrombinase activity of human platelets is inhibited by β2-glycoprotein-I. Biochim Biophys Acta 1986; 884: 142-149
    CrossrefPubMedGoogle Scholar
  • 23 Galli M, Bevers EM, Comfurius P, Barbui T, Zwaal RF A. Effect of antiphospholipid antibodies on procoagulant activity of activated platelets and platelet-derived microvesicles. Brit J Haematol 1993; 83: 466-472
    CrossrefPubMedGoogle Scholar
  • 24 Brandt JT. Antibodies to β2-glycoprotein I inhibit phospholipid dependent coagulation reactions. Thromb Haemost 1993; 70: 598-602
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Exner T, Triplett DA, Tabemer D, Machin SJ. Guidelines for testing and revised criteria for lupus anticoagulants. Thromb Haemost 1991; 65: 320-322
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Jaeger U, Kapiotis S, Pabinger I, Puchhammer E, Kyrie PA, Lechner K. Transient lupus anticoagulant associated with hypoprothrombinemia and Factor XII deficiency following adenovirus infection. Ann Hematol 1993; 67: 95-99
    CrossrefPubMedGoogle Scholar
  • 27 Schousboe I. Contact activation in human plasma is triggered by zinc ion modulation of factor XII (Hageman Factor). Blood Coagul Fibrinol 1993; 4: 671-678
    CrossrefPubMedGoogle Scholar
  • 28 Harboe N, Ingild A. Immunization, isolation of immunoglobulins and estimation of antibody titre. Scand J Immunol 1973; 2 suppl 161-164
    CrossrefPubMedGoogle Scholar
  • 29 Oosting JD, Derksen RH W M, Entjes HT I, Bouma BN, deGroot PG. Lupus anticoagulant activity is frequently dependent on the presence of β2-glycoprotein I. Thromb Haemost 1992; 67: 499-502
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Roubey RA S, Pratt CW, Buyon JP, Winfield JB. Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon β2-glycoprotein I. J Clin Invest 1992; 90: 1100-1104
    CrossrefPubMedGoogle Scholar
  • 31 Schousboe I. The effect of β2-glycoprotein I on the dextransulfate and sulfatide activation of the contact system (Hageman factor system) in the blood coagulation. Int J Biochem 1988; 20: 787-792
    CrossrefPubMedGoogle Scholar
  • 32 Polz E, Kostner GM. The binding of β2-glycoprotein I to human serum lipoproteins. FEBS Lett 1979; 102: 183-186
    CrossrefPubMedGoogle Scholar